RELEASE DATE: July 31, 2020
EXPIRATION DATE: July 31, 2021
Credit Available
- Physicians— maximum of 1.25 AMA PRA Category 1 Credit(s)™
- Nurses— 1.25 Nursing Contact Hours
- Pharmacists— 1.25 Contact Hours (0.125 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The target learning audience for this initiative is neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to the diagnosis and management of patients with NMOSD.
Statement of Need/Program Overview
This activity reviews evidence-based recommendations, challenges, and advances in the diagnosis and treatment of NMO spectrum disorder.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Define symptoms of NMOSD and common diseases that mimic NMOSD
- Summarize consensus diagnostic criteria for NMOSD
- Review diagnostic testing methods for NMOSD
- Employ team-based approaches to the early and accurate diagnosis of NMOSD
- Review novel treatment options for NMOSD
- Apply evidence-based approaches to personalizing treatment for patients with NMOSD
Faculty
Brian G. Weinshenker, MD, FRCP(C)
Consultant, Department of Neurology
Professor of Neurology, College of Medicine
Mayo Clinic
Rochester, MN
Marcelo Matiello, MD
Assistant Professor of Neurology, Harvard Medical School
Director, Massachusetts General Hospital Neurology Inpatient Services
Director, Massachusetts General Hospital Routine and Urgent Teleneurology Program
Associate Director, Neuromyelitis Optica Clinic and Research Unit
Boston, MA
This activity is supported in part by independent education grants from Alexion Pharmaceuticals and Genentech.